ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test
Test Name: ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test
Components: ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy Genetic Test
Price: 4400.0 AED
Sample Condition: Blood
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy.
Test Details: Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN) are X-linked genetic disorders caused by mutations in the ABCD1 gene. ALD primarily affects the nervous system and the adrenal glands, while AMN primarily affects the spinal cord and peripheral nerves. Both disorders are characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues and organs, leading to damage and dysfunction.
NGS (Next-Generation Sequencing) genetic testing is a method used to identify mutations in the ABCD1 gene. This test involves sequencing the entire coding region of the gene, as well as adjacent non-coding regions, to identify all possible mutations. NGS testing is more comprehensive than traditional Sanger sequencing, which only targets specific regions of the gene.
NGS genetic testing for ALD/AMN is typically performed on a blood sample. The test results can confirm a diagnosis of ALD or AMN in individuals with symptoms, or identify carriers of the disease in asymptomatic individuals. Early diagnosis is critical for ALD, as it allows for early intervention and treatment to prevent or delay the onset of symptoms.
Overall, NGS genetic testing for ALD/AMN can provide important information for individuals and families affected by these disorders, including diagnosis, prognosis, and genetic counseling.
| Test Name | ABCD1 Gene AdrenoleukodystrophyAdrenomyeloneuropathy Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with ABCD1 Gene Adrenoleukodystrophy/Adrenomyeloneuropathy |
| Test Details | Adrenoleukodystrophy (ALD) and Adrenomyeloneuropathy (AMN) are X-linked genetic disorders caused by mutations in the ABCD1 gene. ALD primarily affects the nervous system and the adrenal glands, while AMN primarily affects the spinal cord and peripheral nerves. Both disorders are characterized by the accumulation of very long-chain fatty acids (VLCFAs) in tissues and organs, leading to damage and dysfunction. NGS (Next-Generation Sequencing) genetic testing is a method used to identify mutations in the ABCD1 gene. This test involves sequencing the entire coding region of the gene, as well as adjacent non-coding regions, to identify all possible mutations. NGS testing is more comprehensive than traditional Sanger sequencing, which only targets specific regions of the gene. NGS genetic testing for ALD/AMN is typically performed on a blood sample. The test results can confirm a diagnosis of ALD or AMN in individuals with symptoms, or identify carriers of the disease in asymptomatic individuals. Early diagnosis is critical for ALD, as it allows for early intervention and treatment to prevent or delay the onset of symptoms. Overall, NGS genetic testing for ALD/AMN can provide important information for individuals and families affected by these disorders, including diagnosis, prognosis, and genetic counseling. |
